24 September 2021 | News
Nanogen has developed and produced protein subunit vaccine
Image Credit: PIB
Translational Health Science and Technology Institute (THSTI), Department of Biotechnology (DBT), Government of India has entered into a research collaboration with Nanogen Pharmaceutical Biotechnology JSC, a Vietnamese pharmaceutical company, that is developing a new vaccine for COVID-19.
Pham Sanh Chau, the Ambassador of Vietnam to India, led a team that visited THSTI to sign MoU between THSTI and the Nanogen Pharmaceutical Biotechnology JSC.
After having accomplished the pre-clinical trial with high safety and efficacy, Nano Covax is the first COVID-19 vaccine to be approved by Vietnam’s Ministry of Health to conduct clinical trial in Vietnam. Phase 1 of the clinical trial started on December 2020.
Nanogen has developed and produced protein subunit vaccine by using recombinant S-protein subunit binding to silica nanoparticles.
The current manufactory system of Nanogen is capable of manufacturing 20-30 million doses, up to 100 million doses each year to satisfy the domestic demand and export orientation.